With Belviq not launching until June 11, second-quarter's reported sales will only reflect wholesaler stocking and not true patient demand, notes Credit Suisse analyst Ravi Mehrota in a research note.
"But Q3 matters, as does TRx data into the quarter, and TRx will need to meaningfully accelerated to meet the quarter," Mehrota adds. "Q3 would seem to need a TRx of at least around 190,000 for the entire quarter, or an average of around 15,000 TRx per week in the quarter."
Areniacs are also trying to calm their frazzled nerves by comparing initial Belviq weekly scripts to those recorded by Vivus (VVUS) when it launched Qsymia last year. Again, this is a mistake because of the different ways in which the competing weight-loss pills hit the market. Until this week, Qsymia distribution was restricted to mail-order pharmacies while Belviq was launched immediately through retail pharmacies. Vivus also didn't offer free drug samples while Arena and Eisai are.
It's no surprise, then, that on a numeric basis, the early Belviq script numbers are higher than what Qsymia achieved in its first few weeks on the market.What will mattter more for Belviq is what happens to demand once patients are no longer receiving free or discounted drug. With a middling 3 percent, placebo-adjusted weight loss and more than 50 percent of patients failing to lose 5% of their baseline weight at 12 weeks in the drug's pivotal clinical trials, the real concern is that a lot of obese patients won't be taking Belviq for very long, especially if they're forced to pay full price without insurance reimbursement. Areniacs whine constantly about market manipulation and "trapped" shorts, but in reality, the short thesis on Arena has not changed appreciably since Belviq was approved. The drug doesn't work very well and it's expensive. Sales will disappoint, particularly relative to Arena's already lofty valuation. It will take a lot more than two weeks of Belviq prescription data to prove the short thesis right or wrong. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV